OliX Updates Disclosure to Include FDA Application for Phase 2a OLX10212 Trial

• OliX Pharmaceuticals corrected its disclosure Nov. 2, 2026, to reflect an Oct. 31 FDA application for its Phase 2a OLX10212 trial.
• The trial targets 64 patients with bilateral age-related macular degeneration with geographic atrophy.
• US participation will include up to eight sites; the revised trial duration is approximately 35 months from approval, versus 38 months previously.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OliX Pharmaceuticals Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102900257), on November 02, 2026, and is solely responsible for the information contained therein.